Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aromatherapy gel is a topical therapeutic formulation developed and studied by the University Hospital of Strasbourg for the management of pain in patients with De Quervain's disease (stenosing tenosynovitis). De Quervain's disease is characterized by inflammation of the tendons controlling the thumb, often resulting from repetitive strain or musculoskeletal disorders. This specific aromatherapy preparation is being evaluated in clinical trials as a natural alternative to conventional non-steroidal anti-inflammatory drugs (NSAIDs) like diclofenac. The gel aims to provide analgesic and anti-inflammatory effects through the topical application of essential oils, potentially reducing the need for corticosteroid injections or systemic medications while minimizing side effects associated with traditional pharmacological treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aromatherapy gel.